EPRX.TO vs. WELL.TO

Last updated Apr 2, 2026

Compare and contrast key facts about Eupraxia Pharmaceuticals Inc. (EPRX.TO) and WELL Health Technologies Corp. (WELL.TO).

Performance

EPRX.TO vs. WELL.TO - Performance Comparison

The chart below illustrates the hypothetical performance of a CA$10,000 investment in Eupraxia Pharmaceuticals Inc. (EPRX.TO) and WELL Health Technologies Corp. (WELL.TO). The values are adjusted to include any dividend payments, if applicable.

EPRX.TO vs. WELL.TO - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
EPRX.TO Eupraxia Pharmaceuticals Inc.	-0.10%	128.82%	-16.01%	47.12%	48.98%	-64.49%
WELL.TO WELL Health Technologies Corp.	-2.51%	-41.84%	78.18%	35.56%	-42.16%	-41.41%

Fundamentals

Market Cap EPRX.TO : CA$535.49M WELL.TO : CA$586.52M
EPS EPRX.TO : -CA$1.14 WELL.TO : -CA$0.03
PB Ratio EPRX.TO : 7.47 WELL.TO : 0.68
Total Revenue (TTM) EPRX.TO : CA$0.00 WELL.TO : CA$1.40B
Gross Profit (TTM) EPRX.TO : -CA$331.69K WELL.TO : CA$525.08M
EBITDA (TTM) EPRX.TO : -CA$46.56M WELL.TO : CA$161.38M

Returns By Period

In the year-to-date period, EPRX.TO achieves a -0.10% return, which is significantly higher than WELL.TO's -2.51% return.

EPRX.TO

• 1D: 2.69%
• 1M: -9.32%
• YTD: -0.10%
• 6M: 21.29%
• 1Y: 119.36%
• 3Y*: 34.58%
• 5Y*: 13.56%
• 10Y*: —

WELL.TO

• 1D: 1.30%
• 1M: -7.38%
• YTD: -2.51%
• 6M: -26.88%
• 1Y: -10.16%
• 3Y*: -7.15%
• 5Y*: -12.02%
• 10Y*: 69.39%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

EPRX.TO vs. WELL.TO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

EPRX.TO

EPRX.TO Risk / Return Rank: 90
EPRX.TO Sharpe Ratio Rank: 91
EPRX.TO Sortino Ratio Rank: 90
EPRX.TO Omega Ratio Rank: 85
EPRX.TO Calmar Ratio Rank: 92
EPRX.TO Martin Ratio Rank: 93

WELL.TO

WELL.TO Risk / Return Rank: 31
WELL.TO Sharpe Ratio Rank: 29
WELL.TO Sortino Ratio Rank: 27
WELL.TO Omega Ratio Rank: 27
WELL.TO Calmar Ratio Rank: 36
WELL.TO Martin Ratio Rank: 36

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

EPRX.TO vs. WELL.TO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Eupraxia Pharmaceuticals Inc. (EPRX.TO) and WELL Health Technologies Corp. (WELL.TO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	EPRX.TO	WELL.TO	Difference
Sharpe ratio Return per unit of total volatility	2.08	-0.25	+2.33
Sortino ratio Return per unit of downside risk	2.93	-0.07	+3.01
Omega ratio Gain probability vs. loss probability	1.34	0.99	+0.35
Calmar ratio Return relative to maximum drawdown	4.66	-0.15	+4.82
Martin ratio Return relative to average drawdown	14.07	-0.28	+14.35
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

EPRX.TO vs. WELL.TO - Sharpe Ratio Comparison

The current EPRX.TO Sharpe Ratio is 2.08, which is higher than the WELL.TO Sharpe Ratio of -0.25. The chart below compares the historical Sharpe Ratios of EPRX.TO and WELL.TO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	EPRX.TO	WELL.TO	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.08	-0.25	+2.33
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.20	-0.26	+0.47
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.44	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.12	0.17	-0.05

Correlation

The correlation between EPRX.TO and WELL.TO is 0.13, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

EPRX.TO vs. WELL.TO - Dividend Comparison

Neither EPRX.TO nor WELL.TO has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

EPRX.TO vs. WELL.TO - Drawdown Comparison

The maximum EPRX.TO drawdown since its inception was -87.48%, smaller than the maximum WELL.TO drawdown of -98.33%. Use the drawdown chart below to compare losses from any high point for EPRX.TO and WELL.TO.

Drawdown Indicators

	EPRX.TO	WELL.TO	Difference
Max Drawdown Largest peak-to-trough decline	-87.48%	-98.33%	+10.85%
Max Drawdown (1Y) Largest decline over 1 year	-25.60%	-39.43%	+13.83%
Max Drawdown (5Y) Largest decline over 5 years	-85.51%	-70.22%	-15.29%
Max Drawdown (10Y) Largest decline over 10 years	—	-71.51%	—
Current Drawdown Current decline from peak	-17.52%	-57.85%	+40.33%
Average Drawdown Average peak-to-trough decline	-42.98%	-46.16%	+3.18%
Ulcer Index Depth and duration of drawdowns from previous peaks	8.48%	21.96%	-13.48%

Volatility

EPRX.TO vs. WELL.TO - Volatility Comparison

Eupraxia Pharmaceuticals Inc. (EPRX.TO) and WELL Health Technologies Corp. (WELL.TO) have volatilities of 15.87% and 15.47%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	EPRX.TO	WELL.TO	Difference
Volatility (1M) Calculated over the trailing 1-month period	15.87%	15.47%	+0.40%
Volatility (6M) Calculated over the trailing 6-month period	41.79%	31.47%	+10.32%
Volatility (1Y) Calculated over the trailing 1-year period	57.72%	41.85%	+15.87%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	67.78%	45.65%	+22.13%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	67.91%	159.86%	-91.95%

Financials